Skip to content

Eli Lilly

NYSE: LLY · USD

Eli Lilly financials

6 charts

Revenue

USD millions

$22,974M
Eli Lilly Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$5,292.8M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$5,562M; +5.1% vs FY 2009 Q2
FY 2009 Q4$5,934.2M; +6.7% vs FY 2009 Q3
FY 2010 Q1$5,485.5M; −7.6% vs FY 2009 Q4
FY 2010 Q2$5,748.7M; +4.8% vs FY 2010 Q1
FY 2010 Q3$5,654.8M; −1.6% vs FY 2010 Q2
FY 2010 Q4$6,187M; +9.4% vs FY 2010 Q3
FY 2011 Q1$5,839.2M; −5.6% vs FY 2010 Q4
FY 2011 Q2$6,252.8M; +7.1% vs FY 2011 Q1
FY 2011 Q3$6,147.9M; −1.7% vs FY 2011 Q2
FY 2011 Q4$6,046.6M; −1.6% vs FY 2011 Q3
FY 2012 Q1$5,602M; −7.4% vs FY 2011 Q4
FY 2012 Q2$5,600.7M; 0.0% vs FY 2012 Q1
FY 2012 Q3$5,443.3M; −2.8% vs FY 2012 Q2
FY 2012 Q4$5,957.3M; +9.4% vs FY 2012 Q3
FY 2013 Q1$5,602M; −6.0% vs FY 2012 Q4
FY 2013 Q2$5,929.7M; +5.8% vs FY 2013 Q1
FY 2013 Q3$5,772.6M; −2.6% vs FY 2013 Q2
FY 2013 Q4$5,808.8M; +0.6% vs FY 2013 Q3
FY 2014 Q1$4,683.1M; −19.4% vs FY 2013 Q4
FY 2014 Q2$4,935.6M; +5.4% vs FY 2014 Q1
FY 2014 Q3$4,875.6M; −1.2% vs FY 2014 Q2
FY 2014 Q4$5,121.3M; +5.0% vs FY 2014 Q3
FY 2015 Q1$4,644.7M; −9.3% vs FY 2014 Q4
FY 2015 Q2$4,978.7M; +7.2% vs FY 2015 Q1
FY 2015 Q3$4,959.7M; −0.4% vs FY 2015 Q2
FY 2015 Q4$5,375.6M; +8.4% vs FY 2015 Q3
FY 2016 Q1$4,865.1M; −9.5% vs FY 2015 Q4
FY 2016 Q2$5,404.8M; +11.1% vs FY 2016 Q1
FY 2016 Q3$5,191.7M; −3.9% vs FY 2016 Q2
FY 2016 Q4$5,760.5M; +11.0% vs FY 2016 Q3
FY 2017 Q1$5,228.3M; −9.2% vs FY 2016 Q4
FY 2017 Q2$5,824.3M; +11.4% vs FY 2017 Q1
FY 2017 Q3$5,658M; −2.9% vs FY 2017 Q2
FY 2017 Q4$6,160.7M; +8.9% vs FY 2017 Q3
FY 2018 Q1$5,700M; −7.5% vs FY 2017 Q4
FY 2018 Q2$6,355.2M; +11.5% vs FY 2018 Q1
FY 2018 Q3$6,061.9M; −4.6% vs FY 2018 Q2
FY 2018 Q4$6,438.6M; +6.2% vs FY 2018 Q3
FY 2019 Q1$5,092.2M; −20.9% vs FY 2018 Q4
FY 2019 Q2$5,636.7M; +10.7% vs FY 2019 Q1
FY 2019 Q3$5,476.6M; −2.8% vs FY 2019 Q2
FY 2019 Q4$6,114M; +11.6% vs FY 2019 Q3
FY 2020 Q1$5,859.8M; −4.2% vs FY 2019 Q4
FY 2020 Q2$5,499.4M; −6.2% vs FY 2020 Q1
FY 2020 Q3$5,740.6M; +4.4% vs FY 2020 Q2
FY 2020 Q4$7,440M; +29.6% vs FY 2020 Q3
FY 2021 Q1$6,805.6M; −8.5% vs FY 2020 Q4
FY 2021 Q2$6,740.1M; −1.0% vs FY 2021 Q1
FY 2021 Q3$6,772.8M; +0.5% vs FY 2021 Q2
FY 2021 Q4$7,999.9M; +18.1% vs FY 2021 Q3
FY 2022 Q1$7,810M; −2.4% vs FY 2021 Q4
FY 2022 Q2$6,488M; −16.9% vs FY 2022 Q1
FY 2022 Q3$6,941.6M; +7.0% vs FY 2022 Q2
FY 2022 Q4$7,301.8M; +5.2% vs FY 2022 Q3
FY 2023 Q1$6,960M; −4.7% vs FY 2022 Q4
FY 2023 Q2$8,312.1M; +19.4% vs FY 2023 Q1
FY 2023 Q3$9,498.6M; +14.3% vs FY 2023 Q2
FY 2023 Q4$9,353.4M; −1.5% vs FY 2023 Q3
FY 2024 Q1$8,768M; −6.3% vs FY 2023 Q4
FY 2024 Q2$11,302.8M; +28.9% vs FY 2024 Q1
FY 2024 Q3$11,439.1M; +1.2% vs FY 2024 Q2
FY 2024 Q4$13,532.8M; +18.3% vs FY 2024 Q3
FY 2025 Q1$12,728.5M; −5.9% vs FY 2024 Q4
FY 2025 Q2$15,557.7M; +22.2% vs FY 2025 Q1
FY 2025 Q3$17,600.8M; +13.1% vs FY 2025 Q2
FY 2025 Q4$19,292M; +9.6% vs FY 2025 Q3
FY 2026 Q1$19,799M; +2.6% vs FY 2025 Q4
FY 2026 Q2$22,974M; +16.0% vs FY 2026 Q1
Jun 30, 2009 through Sep 25, 2026

Free cash flow

USD millions

—
Eli Lilly Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2Unavailable; Change unavailable vs FY 2009 Q1
FY 2009 Q3Unavailable; Change unavailable vs FY 2009 Q2
FY 2009 Q4Unavailable; Change unavailable vs FY 2009 Q3
FY 2010 Q1Unavailable; Change unavailable vs FY 2009 Q4
FY 2010 Q2Unavailable; Change unavailable vs FY 2010 Q1
FY 2010 Q3Unavailable; Change unavailable vs FY 2010 Q2
FY 2010 Q4Unavailable; Change unavailable vs FY 2010 Q3
FY 2011 Q1Unavailable; Change unavailable vs FY 2010 Q4
FY 2011 Q2Unavailable; Change unavailable vs FY 2011 Q1
FY 2011 Q3Unavailable; Change unavailable vs FY 2011 Q2
FY 2011 Q4Unavailable; Change unavailable vs FY 2011 Q3
FY 2012 Q1Unavailable; Change unavailable vs FY 2011 Q4
FY 2012 Q2Unavailable; Change unavailable vs FY 2012 Q1
FY 2012 Q3Unavailable; Change unavailable vs FY 2012 Q2
FY 2012 Q4Unavailable; Change unavailable vs FY 2012 Q3
FY 2013 Q1Unavailable; Change unavailable vs FY 2012 Q4
FY 2013 Q2Unavailable; Change unavailable vs FY 2013 Q1
FY 2013 Q3Unavailable; Change unavailable vs FY 2013 Q2
FY 2013 Q4Unavailable; Change unavailable vs FY 2013 Q3
FY 2014 Q1Unavailable; Change unavailable vs FY 2013 Q4
FY 2014 Q2Unavailable; Change unavailable vs FY 2014 Q1
FY 2014 Q3Unavailable; Change unavailable vs FY 2014 Q2
FY 2014 Q4Unavailable; Change unavailable vs FY 2014 Q3
FY 2015 Q1Unavailable; Change unavailable vs FY 2014 Q4
FY 2015 Q2Unavailable; Change unavailable vs FY 2015 Q1
FY 2015 Q3Unavailable; Change unavailable vs FY 2015 Q2
FY 2015 Q4Unavailable; Change unavailable vs FY 2015 Q3
FY 2016 Q1Unavailable; Change unavailable vs FY 2015 Q4
FY 2016 Q2Unavailable; Change unavailable vs FY 2016 Q1
FY 2016 Q3Unavailable; Change unavailable vs FY 2016 Q2
FY 2016 Q4Unavailable; Change unavailable vs FY 2016 Q3
FY 2017 Q1Unavailable; Change unavailable vs FY 2016 Q4
FY 2017 Q2Unavailable; Change unavailable vs FY 2017 Q1
FY 2017 Q3Unavailable; Change unavailable vs FY 2017 Q2
FY 2017 Q4Unavailable; Change unavailable vs FY 2017 Q3
FY 2018 Q1Unavailable; Change unavailable vs FY 2017 Q4
FY 2018 Q2Unavailable; Change unavailable vs FY 2018 Q1
FY 2018 Q3Unavailable; Change unavailable vs FY 2018 Q2
FY 2018 Q4Unavailable; Change unavailable vs FY 2018 Q3
FY 2019 Q1$107.6M; Change unavailable vs FY 2018 Q4
FY 2019 Q2$811.2M; +653.9% vs FY 2019 Q1
FY 2019 Q3$1,246.7M; +53.7% vs FY 2019 Q2
FY 2019 Q4Unavailable; Change unavailable vs FY 2019 Q3
FY 2020 Q1$124.1M; Change unavailable vs FY 2019 Q4
FY 2020 Q2$2,213.6M; +1683.7% vs FY 2020 Q1
FY 2020 Q3$1,413.5M; −36.1% vs FY 2020 Q2
FY 2020 Q4Unavailable; Change unavailable vs FY 2020 Q3
FY 2021 Q1$1,397.1M; Change unavailable vs FY 2020 Q4
FY 2021 Q2$1,394.2M; −0.2% vs FY 2021 Q1
FY 2021 Q3$1,294.5M; −7.2% vs FY 2021 Q2
FY 2021 Q4Unavailable; Change unavailable vs FY 2021 Q3
FY 2022 Q1$2,133.8M; Change unavailable vs FY 2021 Q4
FY 2022 Q2$449.7M; −78.9% vs FY 2022 Q1
FY 2022 Q3$1,567.6M; +248.6% vs FY 2022 Q2
FY 2022 Q4Unavailable; Change unavailable vs FY 2022 Q3
FY 2023 Q1Unavailable; Change unavailable vs FY 2022 Q4
FY 2023 Q2Unavailable; Change unavailable vs FY 2023 Q1
FY 2023 Q3Unavailable; Change unavailable vs FY 2023 Q2
FY 2023 Q4Unavailable; Change unavailable vs FY 2023 Q3
FY 2024 Q1Unavailable; Change unavailable vs FY 2023 Q4
FY 2024 Q2Unavailable; Change unavailable vs FY 2024 Q1
FY 2024 Q3Unavailable; Change unavailable vs FY 2024 Q2
FY 2024 Q4Unavailable; Change unavailable vs FY 2024 Q3
FY 2025 Q1Unavailable; Change unavailable vs FY 2024 Q4
FY 2025 Q2Unavailable; Change unavailable vs FY 2025 Q1
FY 2025 Q3Unavailable; Change unavailable vs FY 2025 Q2
FY 2025 Q4Unavailable; Change unavailable vs FY 2025 Q3
FY 2026 Q1Unavailable; Change unavailable vs FY 2025 Q4
FY 2026 Q2Unavailable; Change unavailable vs FY 2026 Q1

Net margin

%

30.88%
Eli Lilly Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q221.89%
FY 2009 Q316.93%
FY 2009 Q415.43%
FY 2010 Q122.75%
FY 2010 Q223.46%
FY 2010 Q323.04%
FY 2010 Q418.9%
FY 2011 Q118.08%
FY 2011 Q219.15%
FY 2011 Q320.11%
FY 2011 Q414.19%
FY 2012 Q118.05%
FY 2012 Q216.49%
FY 2012 Q324.37%
FY 2012 Q413.89%
FY 2013 Q127.63%
FY 2013 Q220.34%
FY 2013 Q320.84%
FY 2013 Q412.52%
FY 2014 Q115.54%
FY 2014 Q214.86%
FY 2014 Q310.27%
FY 2014 Q48.37%
FY 2015 Q111.4%
FY 2015 Q212.07%
FY 2015 Q316.12%
FY 2015 Q48.9%
FY 2016 Q19.05%
FY 2016 Q213.83%
FY 2016 Q314.99%
FY 2016 Q413.4%
FY 2017 Q1-2.12%
FY 2017 Q217.31%
FY 2017 Q39.82%
FY 2017 Q4-26.89%
FY 2018 Q121.36%
FY 2018 Q2-4.09%
FY 2018 Q318.96%
FY 2018 Q417.47%
FY 2019 Q183.3%
FY 2019 Q223.55%
FY 2019 Q322.9%
FY 2019 Q424.46%
FY 2020 Q124.86%
FY 2020 Q225.68%
FY 2020 Q321.05%
FY 2020 Q428.45%
FY 2021 Q119.91%
FY 2021 Q220.63%
FY 2021 Q316.39%
FY 2021 Q421.58%
FY 2022 Q124.36%
FY 2022 Q214.68%
FY 2022 Q320.91%
FY 2022 Q426.54%
FY 2023 Q119.32%
FY 2023 Q221.21%
FY 2023 Q3-0.6%
FY 2023 Q423.41%
FY 2024 Q125.58%
FY 2024 Q226.25%
FY 2024 Q38.48%
FY 2024 Q432.59%
FY 2025 Q121.68%
FY 2025 Q236.38%
FY 2025 Q331.72%
FY 2025 Q434.41%
FY 2026 Q137.36%
FY 2026 Q230.88%

P/E

× · TTM · Daily

39.6×
Eli Lilly P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-02-299.96×2009-12-31
2012-03-3010.22×2009-12-31
2012-04-3010.5×2009-12-31
2012-05-3110.39×2009-12-31
2012-06-2910.89×2009-12-31
2012-07-3111.17×2009-12-31
2012-08-3111.4×2009-12-31
2012-09-2812.03×2009-12-31
2012-10-3112.34×2009-12-31
2012-11-3012.44×2009-12-31
2012-12-3112.51×2009-12-31
2013-01-3113.62×2009-12-31
2013-02-2813.87×2009-12-31
2013-03-2814.41×2009-12-31
2013-04-3014.05×2009-12-31
2013-05-3113.49×2009-12-31
2013-06-2812.46×2009-12-31
2013-07-3113.48×2009-12-31
2013-08-3013.04×2009-12-31
2013-09-3012.77×2009-12-31
2013-10-3112.64×2009-12-31
2013-11-2912.74×2009-12-31
2013-12-3112.94×2009-12-31
2014-01-3113.7×2009-12-31
2014-02-2813×2010-12-31
2014-03-3112.84×2010-12-31
2014-04-3016.45×2014-03-31
2014-05-3016.66×2014-03-31
2014-06-3017.31×2014-03-31
2014-07-3117×2014-03-31
2014-08-2917.69×2014-03-31
2014-09-3018.05×2014-03-31
2014-10-3118.46×2014-03-31
2014-11-2818.96×2014-03-31
2014-12-3119.2×2014-03-31
2015-01-3020.04×2014-03-31
2015-02-2731.41×2014-12-31
2015-03-3132.52×2014-12-31
2015-04-3032.17×2014-12-31
2015-05-2935.32×2014-12-31
2015-06-3037.37×2014-12-31
2015-07-3143.73×2015-06-30
2015-08-3142.61×2015-06-30
2015-09-3043.3×2015-06-30
2015-10-3042.21×2015-06-30
2015-11-3037.05×2015-09-30
2015-12-3138.06×2015-09-30
2016-01-2935.72×2015-09-30
2016-02-2931.84×2015-12-31
2016-03-3131.84×2015-12-31
2016-04-2933.4×2015-12-31
2016-05-3134.4×2016-03-31
2016-06-3036.1×2016-03-31
2016-07-2935.63×2016-06-30
2016-08-3133.43×2016-06-30
2016-09-3034.5×2016-06-30
2016-10-3132.05×2016-09-30
2016-11-3029.13×2016-09-30
2016-12-3031.92×2016-09-30
2017-01-3133.43×2016-09-30
2017-02-2832.18×2016-12-31
2017-03-3132.69×2016-12-31
2017-04-2831.89×2016-12-31
2017-05-3138.44×2017-03-31
2017-06-3039.76×2017-03-31
2017-07-3135.71×2017-06-30
2017-08-3135.12×2017-06-30
2017-09-2936.95×2017-06-30
2017-10-3138.9×2017-09-30
2017-11-3040.18×2017-09-30
2017-12-2940.09×2017-09-30
2018-01-3138.66×2017-09-30
2018-02-28—2017-12-31
2018-03-29—2017-12-31
2018-04-3075.71×2018-03-31
2018-05-3179.42×2018-03-31
2018-06-2979.69×2018-03-31
2018-07-31—2018-06-30
2018-08-31—2018-06-30
2018-09-28—2018-06-30
2018-10-31—2018-06-30
2018-11-30—2018-06-30
2018-12-31—2018-06-30
2019-01-31—2018-06-30
2019-02-2839.91×2018-12-31
2019-03-2941.01×2018-12-31
2019-04-3036.99×2018-12-31
2019-05-3136.64×2018-12-31
2019-06-2835.01×2018-12-31
2019-07-3134.43×2018-12-31
2019-08-3035.7×2018-12-31
2019-09-3035.34×2018-12-31
2019-10-3136.01×2018-12-31
2019-11-2937.09×2018-12-31
2019-12-3141.54×2018-12-31
2020-01-3144.13×2018-12-31
2020-02-2813.89×2019-12-31
2020-03-3115.27×2019-12-31
2020-04-3017.02×2019-12-31
2020-05-2916.84×2019-12-31
2020-06-3018.07×2019-12-31
2020-07-3116.55×2019-12-31
2020-08-3124.06×2020-06-30
2020-09-3024×2020-06-30
2020-10-3021.34×2020-09-30
2020-11-3023.82×2020-09-30
2020-12-3127.61×2020-09-30
2021-01-2934.01×2020-09-30
2021-02-2630.25×2020-12-31
2021-03-3127.58×2020-12-31
2021-04-3026.98×2020-12-31
2021-05-2829.91×2021-03-31
2021-06-3034.37×2021-03-31
2021-07-3036.47×2021-03-31
2021-08-3138.73×2021-06-30
2021-09-3034.65×2021-06-30
2021-10-2938.85×2021-09-30
2021-11-3037.83×2021-09-30
2021-12-3142.12×2021-09-30
2022-01-3137.42×2021-09-30
2022-02-2838.12×2021-09-30
2022-03-3143.67×2021-09-30
2022-04-2944.55×2021-09-30
2022-05-3147.8×2021-09-30
2022-06-3049.45×2021-09-30
2022-07-2950.28×2021-09-30
2022-08-3145.94×2021-09-30
2022-09-3049.31×2021-09-30
2022-10-3155.22×2021-09-30
2022-11-3056.59×2021-09-30
2022-12-3055.79×2021-09-30
2023-01-3152.48×2021-09-30
2023-02-2847.46×2021-09-30
2023-03-3152.37×2021-09-30
2023-04-2860.37×2021-09-30
2023-05-3165.49×2021-09-30
2023-06-3071.52×2021-09-30
2023-07-3169.32×2021-09-30
2023-08-3184.52×2021-09-30
2023-09-2981.91×2021-09-30
2023-10-3184.48×2021-09-30
2023-11-3090.13×2021-09-30
2023-12-2988.9×2021-09-30
2024-01-3198.46×2021-09-30
2024-02-29129.99×2023-12-31
2024-03-28134.18×2023-12-31
2024-04-30134.72×2023-12-31
2024-05-31120.78×2024-03-31
2024-06-28133.31×2024-03-31
2024-07-31118.42×2024-03-31
2024-08-30118.23×2024-06-30
2024-09-30109.1×2024-06-30
2024-10-3189.72×2024-09-30
2024-11-2986×2024-09-30
2024-12-3183.47×2024-09-30
2025-01-3187.7×2024-09-30
2025-02-2899.54×2024-09-30
2025-03-3189.3×2024-09-30
2025-04-3097.2×2024-09-30
2025-05-3079.76×2024-09-30
2025-06-3084.29×2024-09-30
2025-07-3180.02×2024-09-30
2025-08-2979.21×2024-09-30
2025-09-3082.5×2024-09-30
2025-10-3193.3×2024-09-30
2025-11-28116.29×2024-09-30
2025-12-31116.2×2024-09-30
2026-01-30112.14×2024-09-30
2026-02-2745.78×2025-12-31
2026-03-3140.02×2025-12-31
2026-04-3040.67×2025-12-31
2026-05-2939.17×2026-03-31
2026-06-3042.51×2026-03-31
2026-07-3140.72×2026-03-31
2026-08-3138.7×2026-06-30
2026-09-2539.6×2026-06-30
Mean 44.6×Median 36.66×8% above median

ROIC

% · Annual / TTM

39.7%
Eli Lilly ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q419.06%
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q412.07%
FY 2016 Q111.91%
FY 2016 Q212.27%
FY 2016 Q311.99%
FY 2016 Q414.5%
FY 2017 Q19.99%
FY 2017 Q210.89%
FY 2017 Q39.59%
FY 2017 Q4—
FY 2018 Q14.86%
FY 2018 Q2—
FY 2018 Q32.02%
FY 2018 Q418.39%
FY 2019 Q112.59%
FY 2019 Q224.82%
FY 2019 Q3—
FY 2019 Q427.94%
FY 2020 Q129.93%
FY 2020 Q228.55%
FY 2020 Q3—
FY 2020 Q430.14%
FY 2021 Q124.98%
FY 2021 Q226.56%
FY 2021 Q328.61%
FY 2021 Q428.13%
FY 2022 Q131.61%
FY 2022 Q231.64%
FY 2022 Q329.71%
FY 2022 Q427.73%
FY 2023 Q122.45%
FY 2023 Q225.4%
FY 2023 Q318.26%
FY 2023 Q417.74%
FY 2024 Q119.17%
FY 2024 Q222.23%
FY 2024 Q323.49%
FY 2024 Q427.65%
FY 2025 Q126.17%
FY 2025 Q229.96%
FY 2025 Q338.28%
FY 2025 Q439.65%
FY 2026 Q142.47%
FY 2026 Q239.7%

Capital allocation

% of tracked cash uses

$4,020M
Eli Lilly capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q2UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FY 2009 Q3UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FY 2009 Q4Unavailable0% · $0MUnavailable90.4% · $3,764.5M9.6% · $400M100% · $4,164.5M
FY 2010 Q1UnavailableUnavailableUnavailable100% · $539.2M0% · $0M100% · $539.2M
FY 2010 Q2UnavailableUnavailableUnavailable100% · $536.7MUnavailable100% · $536.7M
FY 2010 Q3Unavailable24.8% · $180.3MUnavailable75.01% · $545.3M0.19% · $1.4M100% · $727M
FY 2010 Q4Unavailable34.02% · $280.7MUnavailable65.94% · $544.1M0.05% · $0.4M100% · $825.2M
FY 2011 Q1Unavailable0% · $0MUnavailable90.87% · $543.2M9.13% · $54.6M100% · $597.8M
FY 2011 Q2Unavailable0% · $0MUnavailable100% · $552.1M0% · $0M100% · $552.1M
FY 2011 Q3Unavailable36.27% · $307.8MUnavailable63.73% · $540.9M0% · $0M100% · $848.7M
FY 2011 Q4Unavailable0% · $0MUnavailable100% · $543.9M0% · $0M100% · $543.9M
FY 2012 Q1Unavailable8.72% · $195.4M0% · $0M24.31% · $544.6M66.96% · $1,500M100% · $2,240M
FY 2012 Q2Unavailable0.7% · $3.9M0% · $0M99.3% · $550.4M0% · $0M100% · $554.3M
FY 2012 Q3Unavailable0% · $0M0% · $0M100% · $544.2M0% · $0M100% · $544.2M
FY 2012 Q4Unavailable0% · $0M56.78% · $721.1M43.17% · $548.2M0.05% · $0.6M100% · $1,269.9M
FY 2013 Q1Unavailable0% · $0M69.25% · $1,198.1M30.7% · $531.1M0.05% · $0.9M100% · $1,730.1M
FY 2013 Q2Unavailable0% · $0M0% · $0M99.85% · $533M0.15% · $0.8M100% · $533.8M
FY 2013 Q3Unavailable7.63% · $43.7M0% · $0M92.14% · $527.7M0.23% · $1.3M100% · $572.7M
FY 2013 Q4Unavailable0% · $0M48.24% · $500M51.03% · $528.9M0.72% · $7.5M100% · $1,036.4M
FY 2014 Q1Unavailable0% · $0M3.48% · $55M33.15% · $524.1M63.37% · $1,002M100% · $1,581.1M
FY 2014 Q2Unavailable43.93% · $551.4M11.55% · $145M41.98% · $526.9M2.53% · $31.8M100% · $1,255.1M
FY 2014 Q3Unavailable0% · $0M36.34% · $300M63.6% · $525M0.06% · $0.5M100% · $825.5M
FY 2014 Q4Unavailable0% · $0M36.33% · $300M63.61% · $525.2M0.06% · $0.5M100% · $825.7M
FY 2015 Q1Unavailable86.27% · $5,276.7M5.08% · $310.6M8.63% · $527.9M0.02% · $1.5M100% · $6,116.7M
FY 2015 Q2Unavailable0% · $0M4.78% · $124.9M20.64% · $539.8M74.58% · $1,950M100% · $2,614.7M
FY 2015 Q3Unavailable1.85% · $11.1M10.19% · $61.1M87.73% · $526.3M0.23% · $1.4M100% · $599.9M
FY 2015 Q4UnavailableUnavailable31.96% · $252.9M67.4% · $533.3M0.64% · $5.1M100% · $791.3M
FY 2016 Q1Unavailable0% · $0M35.79% · $300.1M64.21% · $538.3M0% · $0M100% · $838.4M
FY 2016 Q2Unavailable7.68% · $45M0% · $0M92.31% · $541.2M0.02% · $0.1M100% · $586.3M
FY 2016 Q3Unavailable0% · $0M0% · $0M99.98% · $537.9M0.02% · $0.1M100% · $538M
FY 2016 Q4Unavailable0% · $0M9.98% · $60M90.02% · $541.1M0% · $0M100% · $601.1M
FY 2017 Q1Unavailable42.83% · $882.1M0% · $0M26.58% · $547.4M30.6% · $630.2M100% · $2,059.7M
FY 2017 Q2Unavailable0% · $0M26.69% · $199.9M73.27% · $548.7M0.04% · $0.3M100% · $748.9M
FY 2017 Q3Unavailable0% · $0M0% · $0M99.98% · $547.7M0.02% · $0.1M100% · $547.8M
FY 2017 Q4Unavailable0% · $0M15.41% · $99.9M84.59% · $548.3M0% · $0M100% · $648.2M
FY 2018 Q1Unavailable0% · $0M44.22% · $1,100M23.61% · $587.3M32.17% · $800.3M100% · $2,487.6M
FY 2018 Q2Unavailable0% · $0M54.92% · $950.7M33.46% · $579.3M11.62% · $201.2M100% · $1,731.2M
FY 2018 Q3Unavailable0% · $0M63.59% · $1,000M36.41% · $572.6M0% · $0M100% · $1,572.6M
FY 2018 Q4Unavailable0% · $0M65.47% · $1,100M34.08% · $572.6M0.45% · $7.6M100% · $1,680.2M
FY 2019 Q11.72% · $203.7M58.33% · $6,917.7M29.51% · $3,500M5.37% · $637.2M5.06% · $600M100% · $11,858.6M
FY 2019 Q228.66% · $240.3M0% · $0M0% · $0M71.32% · $598M0.02% · $0.2M100% · $838.5M
FY 2019 Q318.15% · $263.4M0% · $0M41.35% · $600M40.49% · $587.4M0.01% · $0.1M100% · $1,450.9M
FY 2019 Q4Unavailable0% · $0M9.51% · $300M18.62% · $587.2M71.86% · $2,266.1M100% · $3,153.3M
FY 2020 Q110.11% · $258.3M33.24% · $849.3M19.57% · $500M26.27% · $671.3M10.81% · $276.3M100% · $2,555.2M
FY 2020 Q229.48% · $281.8M0% · $0M0% · $0M70.52% · $674.2M0% · $0M100% · $956M
FY 2020 Q336.92% · $393.1M0% · $0M0% · $0M63.08% · $671.6M0% · $0M100% · $1,064.7M
FY 2020 Q4Unavailable0% · $0M0% · $0M99.97% · $670M0.03% · $0.2M100% · $670.2M
FY 2021 Q116.48% · $300.3M41.01% · $747.4M0% · $0M42.51% · $774.8M0% · $0M100% · $1,822.5M
FY 2021 Q223.11% · $381.3M0% · $0M30.31% · $500M46.57% · $768.3M0% · $0M100% · $1,649.6M
FY 2021 Q311.18% · $336.8M0% · $0M0% · $0M25.57% · $770.4M63.25% · $1,905.3M100% · $3,012.5M
FY 2021 Q4Unavailable0% · $0M49.23% · $750M50.76% · $773.3M0.01% · $0.1M100% · $1,523.4M
FY 2022 Q110.56% · $365.4M0% · $0M43.34% · $1,500M25.59% · $885.5M20.52% · $710.1M100% · $3,461M
FY 2022 Q217.63% · $371M0% · $0M0% · $0M41.99% · $883.7M40.38% · $849.9M100% · $2,104.6M
FY 2022 Q341.16% · $617.2M0% · $0M0% · $0M58.84% · $882.2M0% · $0M100% · $1,499.4M
FY 2022 Q4Unavailable27.01% · $327.2M0% · $0M72.99% · $884.4M0% · $0M100% · $1,211.6M
FY 2023 Q1UnavailableUnavailable42.44% · $750M57.56% · $1,017.2M0% · $0M100% · $1,767.2M
FY 2023 Q2UnavailableUnavailable0% · $0M100% · $1,017.8M0% · $0M100% · $1,017.8M
FY 2023 Q3UnavailableUnavailable0% · $0M100% · $1,016.2M0% · $0M100% · $1,016.2M
FY 2023 Q4UnavailableUnavailable0% · $0M100% · $1,018.1M0% · $0M100% · $1,018.1M
FY 2024 Q1UnavailableUnavailable0% · $0M100% · $1,169.2MUnavailable100% · $1,169.2M
FY 2024 Q2UnavailableUnavailable0% · $0M100% · $1,172.4MUnavailable100% · $1,172.4M
FY 2024 Q3UnavailableUnavailable27.59% · $446.1M72.41% · $1,170.5M0% · $0M100% · $1,616.6M
FY 2024 Q4UnavailableUnavailable63.74% · $2,053.9M36.26% · $1,168.3M0% · $0M100% · $3,222.2M
FY 2025 Q1UnavailableUnavailable47.13% · $1,200M52.87% · $1,346.3M0% · $0M100% · $2,546.3M
FY 2025 Q2UnavailableUnavailable24.57% · $692.2M47.81% · $1,347M27.62% · $778.1M100% · $2,817.3M
FY 2025 Q3UnavailableUnavailable34.49% · $708.1M65.51% · $1,345.2M0% · $0M100% · $2,053.3M
FY 2025 Q4UnavailableUnavailable52.84% · $1,507.7M47.16% · $1,345.5MUnavailable100% · $2,853.2M
FY 2026 Q1UnavailableUnavailable50.62% · $2,356M33.26% · $1,548M16.12% · $750M100% · $4,654M
FY 2026 Q2UnavailableUnavailable39.83% · $1,601M38.46% · $1,546M21.72% · $873M100% · $4,020M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Eli Lilly.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources